Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine Grosset

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|July 28, 2005
Spheramine Titan/ScheringDonald Grosset, Katherine Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|December 8, 2004
Trial of subtherapeutic pergolide in de novo Parkinson's diseaseKatherine Grosset, Donald Grosset, Andrew Lees, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 25, 2004
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion tableKatherine Grosset, Fiona Needleman, Graeme Macphee, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 25, 2019
Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studiesCallum Smith, Naveed Malek, Katherine Grosset, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 5, 2009
Adherence to antiparkinson medication in a multicenter European studyDonald Grosset, Angelo Antonini, Margherita Canesi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 22, 2022
Genetics of validated Parkinson's disease subtypes in the Oxford Discovery and Tracking Parkinson's cohortsMichael Lawton, Manuela Mx Tan, Yoav Ben-Shlomo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 16, 2022
Combining biomarkers for prognostic modelling of Parkinson's diseaseNirosen Vijiaratnam, Michael Lawton, Amanda J Heslegrave, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Opinion in Investigational Drugs (London, England : 2000)|July 28, 2005
Spheramine Titan/ScheringDonald Grosset, Katherine Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|December 8, 2004
Trial of subtherapeutic pergolide in de novo Parkinson's diseaseKatherine Grosset, Donald Grosset, Andrew Lees, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 25, 2004
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion tableKatherine Grosset, Fiona Needleman, Graeme Macphee, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 25, 2019
Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studiesCallum Smith, Naveed Malek, Katherine Grosset, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 5, 2009
Adherence to antiparkinson medication in a multicenter European studyDonald Grosset, Angelo Antonini, Margherita Canesi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 22, 2022
Genetics of validated Parkinson's disease subtypes in the Oxford Discovery and Tracking Parkinson's cohortsMichael Lawton, Manuela Mx Tan, Yoav Ben-Shlomo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 16, 2022
Combining biomarkers for prognostic modelling of Parkinson's diseaseNirosen Vijiaratnam, Michael Lawton, Amanda J Heslegrave, et al.
Pageof 1